Clinical trials: Blood Transfusion, Autologous
Heart Transplantation
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries.
- Trial name
- THYTECH (NCT04924491)
- Testing
- Autologous thyTreg
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Rafael Correa-Rocha
Anemia, Blood Transfusions, Autologous
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa at doses of 150, 300, or 600 units per kilogram of body weight versus placebo in facilitating presurgical collection of blood for self-donation…
- Conditions
- Anemia, Blood Transfusions, Autologous, Orthopedic Procedures
- Trial name
- NCT00270140
- Testing
- epoetin alfa
- Volunteers
- 17 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Cognitive; Disorder, Due to General Medical Condition
Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass
Haemo-autologous Antegrade Repriming (HAR) is a procedure based in the combination of evidence proven measures designed to reduce the haemodilution caused by establishing the cardiopulmonary bypass (CPB) during cardiac surgery.
- Conditions
- Anemia, Cognitive; Disorder, Due to General Medical Condition, Embolism, Air, Transfusion
- Trial name
- HARjbm1 (NCT03720184)
- Testing
- HAR
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Juan Blanco Morillo
Ovarian Cancer
Chemotherapy Supported by Autologous Hematopoietic Stem Cells
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer.
- Trial name
- NCT05401162
- Testing
- Autologous blood transfusion with haematopoietic stem cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing University Cancer Hospital
Healthy
The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers
A single-site, single-blind study of ascending doses of Lyophilized Plasma in normal healthy volunteers.
- Trial name
- NCT00968487
- Testing
- Lyophilized Plasma, Fresh Frozen Plasma
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- HemCon Medical Technologies, Inc
Chronic Granulomatous Disease, Infection
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Background: CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections.
- Trial name
- NCT05189925
- Testing
- gp91 Grans
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronary Artery Disease
Antegrade Autologous Blood Reinfusion After CPB
This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery…
- Trial name
- NCT07420582
- Testing
- Antegrade Pump Blood Reinfusion, No Anterograde Pump Blood Reinfusion
- Where
- Turkey (Türkiye)
- Volunteers
- 130 people
- Sponsor
- Kocaeli City Hospital
Pancreaticoduodenectomy, Pancreatectomy
Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.
The purpose of this study is to demonstrate the safety and benefit of auto-transfusion filtered blood in patients undergoing major surgical oncology procedures.
- Conditions
- Pancreaticoduodenectomy, Pancreatectomy, Esophagectomy, Gastrectomy
- Trial name
- Cellsaver (NCT00708513)
- Where
- 2 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Louisville
Beta-Thalassemia, Thalassemia
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD).
- Conditions
- Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn
- Trial name
- NCT05477563
- Testing
- CTX001
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
β-thalassemia
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector…
- Trial name
- NCT05773729
- Testing
- BD211
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai BDgene Co., Ltd.
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
- Trial name
- NCT06355739
- Testing
- CAR T cell injection
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhu Xiaofan
Beta-Thalassemia, Thalassemia
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT).
- Conditions
- Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases
- Trial name
- NCT03655678
- Testing
- CTX001
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 59 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Thalassemia, Beta, Thalassemia Major
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.
- Trial name
- NCT06041620
- Testing
- VGB-Ex01
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diabetic Wounds, Platelet Rich Plasma
Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial
Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect.
- Conditions
- Diabetic Wounds, Platelet Rich Plasma, Allogeneic Blood Transfusions, Renal Dysfunction
- Trial name
- NCT07020559
- Testing
- allogeneic platelet plasma, autologous platelet plasma
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Peking University Third Hospital
Out of Hospital Cardiac Arrest, Cardiac Arrest
"The Effect of the Use of an Autotransfusion Device on Hemodynamic Parameters During Resuscitation".
The purpose of the research (pilot study) is to determine the impact of the use of the autotransfusion device on hemodynamic parameters during resuscitation.
- Trial name
- NCT06153160
- Testing
- HemaShock device
- Where
- 2 sites in Slovenia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Maribor
Blood Transfusion, Autologous, Blood Doping
Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling
A total of 40 subjects will be recruited for participation in this study. 20 subjects (10 males and 10 females) will be randomized to the active group (those receiving re-infusion of autologous blood) and 20 subjects (10 males…
- Trial name
- NCT02684747
- Testing
- Autologous Transfusion
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Utah
C.Surgical Procedure; Cardiac
Prospective Trial of Autologous Platelet Rich Plasma in Aortic Surgery
The purpose of this study is to determine whether autologous platelet rich plasma (APRP)is effective in reducing allogeneic blood transfusions during aortic surgery using deep hypothermic circulatory arrest.
- Trial name
- NCT02513862
- Testing
- Autologous Platelet-Rich Plasma Harvest Technique
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hongwen Ji
Placenta Accreta Spectrum
Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion
Placenta accreta spectrum (PAS) disorders are associated with increased maternal morbidity and mortality related to life-threatening hemorrhage, and greater potential need for blood transfusion.
- Trial name
- NCT04927988
- Testing
- Ringer's Lactated
- Where
- China
- Sponsor
- Maternal and Child Health Hospital of Foshan
Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.
- Conditions
- Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
- Trial name
- NCT06363760
- Testing
- Safety and efficacy assessments
- Where
- 18 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Editas Medicine, Inc.
Blood and Lymphatic Diseases
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
Primary Objectives: Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST- 400 in participants with transfusion-dependent beta-thalassemia (TDT) Secondary Objectives: Long-term efficacy of the…
- Trial name
- NCT05145062
- Testing
- BIVV003, ST-400
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sangamo Therapeutics